Cancel
Dimitry S.A. Nuyten
Chief Medical Officer
@
Arcus Biosciences
l1.2.71h78x@lj51hvk6.v76
Sign up to see email
Known information
- Joined Arcus Biosciences in August 2022
- Previously served as Chief Medical Officer at Nektar Therapeutics and Aduro Biotech
- Was Vice President and Immuno-Oncology Development Leader at Pfizer until 2019
- Responsible for the full development program and registrational strategy for Bavencio® at Pfizer
- Led early development for immuno-oncology at Pfizer
- Served as Group Medical Director at Bristol-Myers Squibb in the early development oncology group
- Received an MD from the University of Groningen
- Received a PhD from the University of Amsterdam
- Trained as a radiation oncologist at the Netherlands Cancer Institute in Amsterdam
- Was a visiting scientist at Stanford University from 2004-2005
About Arcus Biosciences
Arcus Biosciences develops differentiated molecules and combination therapies for cancer treatment, with a clinical pipeline that includes domvanalimab, etrumadenant, and zimberelimab. The company partners with Gilead Sciences and Taiho Pharmaceutical and conducts global clinical trials in various cancer types.
Report inaccurate information